Effects of beraprost sodium and prostaglandin E1 on skin blood flow in diabetic rats and normal dogs. 1996

Y Ueno, and N Yamada, and H Koike, and S Nishio
Basic Research Laboratories, Toray Industries Inc., Kanagawa, Japan.

1. The present study was undertaken to compare the effects of beraprost sodium (BPS), a stable prostaglandin I2 analog, with prostaglandin E1 (PGE1) on the skin blood flow in anesthesized diabetic rats and anesthetized dogs. 2. In anesthetized diabetic rats, BPS, but not PGE1, caused a dose-dependent and significant increase in femoral skin blood flow. 3. In anesthetized dogs, PGE1 significantly increased femoral arterial blood flow than BPS. However, BPS significantly increased in-step skin blood flow than PGE1. 4. The above data suggest that BPS may be clinically useful for the treatment of circulatory insufficiency of lower extremities in diabetic patients.

UI MeSH Term Description Entries
D008297 Male Males
D010975 Platelet Aggregation Inhibitors Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. Antiaggregants, Platelet,Antiplatelet Agent,Antiplatelet Agents,Antiplatelet Drug,Blood Platelet Aggregation Inhibitor,Blood Platelet Antagonist,Blood Platelet Antiaggregant,PAR-1 Antagonists,Platelet Aggregation Inhibitor,Platelet Antagonist,Platelet Antagonists,Platelet Antiaggregant,Platelet Antiaggregants,Platelet Inhibitor,Protease-Activated Receptor-1 Antagonists,Antiplatelet Drugs,Blood Platelet Aggregation Inhibitors,Blood Platelet Antagonists,Blood Platelet Antiaggregants,Platelet Inhibitors,Agent, Antiplatelet,Aggregation Inhibitor, Platelet,Antagonist, Blood Platelet,Antagonist, Platelet,Antiaggregant, Blood Platelet,Antiaggregant, Platelet,Drug, Antiplatelet,Inhibitor, Platelet,Inhibitor, Platelet Aggregation,PAR 1 Antagonists,Platelet Antagonist, Blood,Platelet Antiaggregant, Blood,Protease Activated Receptor 1 Antagonists
D011464 Epoprostenol A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from PROSTAGLANDIN ENDOPEROXIDES in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension (HYPERTENSION, PULMONARY). Prostacyclin,Prostaglandin I2,Epoprostanol,Epoprostenol Sodium,Epoprostenol Sodium Salt, (5Z,9alpha,11alpha,13E,15S)-Isomer,Flolan,Prostaglandin I(2),Veletri
D012039 Regional Blood Flow The flow of BLOOD through or around an organ or region of the body. Blood Flow, Regional,Blood Flows, Regional,Flow, Regional Blood,Flows, Regional Blood,Regional Blood Flows
D003921 Diabetes Mellitus, Experimental Diabetes mellitus induced experimentally by administration of various diabetogenic agents or by PANCREATECTOMY. Alloxan Diabetes,Streptozocin Diabetes,Streptozotocin Diabetes,Experimental Diabetes Mellitus,Diabete, Streptozocin,Diabetes, Alloxan,Diabetes, Streptozocin,Diabetes, Streptozotocin,Streptozocin Diabete
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005260 Female Females
D000527 Alprostadil A potent vasodilator agent that increases peripheral blood flow. PGE1,Prostaglandin E1,Caverject,Edex,Lipo-PGE1,Minprog,Muse,PGE1alpha,Prostaglandin E1alpha,Prostavasin,Prostin VR,Prostine VR,Sugiran,Vasaprostan,Viridal,Lipo PGE1
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

Y Ueno, and N Yamada, and H Koike, and S Nishio
January 1998, European surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes,
Y Ueno, and N Yamada, and H Koike, and S Nishio
July 1986, Masui. The Japanese journal of anesthesiology,
Y Ueno, and N Yamada, and H Koike, and S Nishio
June 1976, European journal of pharmacology,
Y Ueno, and N Yamada, and H Koike, and S Nishio
February 1971, The American journal of physiology,
Y Ueno, and N Yamada, and H Koike, and S Nishio
January 2009, American journal of nephrology,
Y Ueno, and N Yamada, and H Koike, and S Nishio
February 1996, Japanese journal of pharmacology,
Y Ueno, and N Yamada, and H Koike, and S Nishio
June 1984, Surgery,
Y Ueno, and N Yamada, and H Koike, and S Nishio
August 1982, Masui. The Japanese journal of anesthesiology,
Y Ueno, and N Yamada, and H Koike, and S Nishio
April 1987, Investigative ophthalmology & visual science,
Y Ueno, and N Yamada, and H Koike, and S Nishio
March 1993, Nippon Ganka Gakkai zasshi,
Copied contents to your clipboard!